A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:eLife
Auteurs principaux: Jeay, Sébastien, Gaulis, Swann, Ferretti, Stéphane, Bitter, Hans, Ito, Moriko, Valat, Thérèse, Murakami, Masato, Ruetz, Stephan, Guthy, Daniel A, Rynn, Caroline, Jensen, Michael R, Wiesmann, Marion, Kallen, Joerg, Furet, Pascal, Gessier, François, Holzer, Philipp, Masuya, Keiichi, Würthner, Jens, Halilovic, Ensar, Hofmann, Francesco, Sellers, William R, Graus Porta, Diana
Format: Artigo
Langue:Inglês
Publié: eLife Sciences Publications, Ltd 2015
Sujets:
Human Biology and Medicine
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468608/
https://ncbi.nlm.nih.gov/pubmed/25965177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.06498
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires